Project Grant R01CA316385
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $682,140 for Project Grant R01CA315856 on June 4, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of SPIDER (Synthetic Potentiated Immunogenic Depot Engaged by Radiation), a localized drug delivery platform designed to improve treatment outcomes for locally advanced non-small cell lung cancer. SPIDER uses radiation-responsive...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $424,256 to The General Hospital Corporation (Massachusetts General Hospital, Research Management Division) on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a computational framework for optimal immune monitoring during cancer treatment. The project constructs compartmental models connecting tissue-level lymphocyte dynamics to blood count data,...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $2,054,733 Cooperative Agreement to Massachusetts General Hospital's Research Management Division, effective September 1, 2025 through August 31, 2028, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and optimization of novel chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer, specifically advancing MESO-FAP CAR-TEAM cells that simultaneously target...
- The National Institute of Biomedical Imaging and Bioengineering (part of the Department of Health and Human Services National Institutes of Health) awarded $1.314 million to Massachusetts General Hospital on June 2, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop quantitative point-of-care MRI for breast cancer screening. The research addresses the limitations of current breast cancer screening modalities by...